Summary of Key Points
Shenzhen Yimu Feng Biology is a CAR-T therapy company founded by a former executive from Fosun, focusing on the treatment of solid tumors such as gastric cancer and pancreatic cancer. Since its establishment in 2020, the company has attracted six rounds of financing ( totaling 973 million yuan) thanks to its star team and impressive clinical data. Its valuation has increased by 40 times in five years, and it is now preparing for an IPO on the Hong Kong Stock Exchange. However, the company has not yet turned a profit; in the first half of 2026, it incurred a net loss of 109 million yuan, and its current funds will only last for 21 months. The main challenges facing the IPO are: while investors see the potential of CAR-T therapy for solid tumors, there are three major hurdles to commercialization—competing products that have already been launched, high costs associated with licensing core intellectual property (IP), and high pricing that may deter patients.
I. Team + Capital: Why a 40-fold Valuation Increase in Five Years?
Yimu Feng’s rapid rise can be attributed to its talented founding team. Dr. Sun Minmin, the founder, played a key role in bringing China’s first CAR-T product (Yikaida) to market under Fosun Kite, which was priced at 1.2 million yuan. The company’s core management includes experts from various fields such as production (CTO from Fosun Kite), research and development (former executives from Legend Biotech), and clinical trials (from multinational companies like Novartis), creating a highly complementary team.
Capital has also been generous: the Fosun group (Pengfu Shenzhen) is the largest institutional shareholder, with well-known VCs such as Guotou Venture Capital and Wei Wu Capital continuously investing. After six rounds of financing over five years, the cost per share increased from 0.8 yuan to 8.74 yuan, and with additional share issuance, the overall valuation has quadrupled. More importantly, investors voluntarily gave up special rights such as the right to redeem their shares before the IPO, indicating their confidence in the company’s ability to go public and generate revenue.
II. Core Products: The “Potential Stocks” of CAR-T Therapy for Solid Tumors
Yimu Feng’s strength lies in its two CAR-T products targeting solid tumors, which account for 90% of cancer cases and have a high demand for treatment:
- IMC002 (for gastric/pancreatic cancer): This is the second-fastest-moving CLDN18.2-targeted CAR-T therapy in global clinical trials. The clinical data are impressive: patients with advanced gastric cancer who received this treatment lived for an average of 18.2 months, three times longer than those treated with standard methods (6.5 months), and the tumor shrinkage rate was 69.2%. IMC002 has also received fast-track approval from the US FDA, with plans to apply for market authorization in 2027.
- IMC001 (for multiple cancers): This is the only EpCAM CAR-T therapy globally approved by both the US and Chinese regulatory agencies, suitable for treating gastric cancer, colorectal cancer, ovarian cancer, and other types of cancer. Some patients have seen their tumors shrink to a size suitable for surgery, with survival periods exceeding 30 months, indicating significant potential.
Technologically, Yimu Feng has adopted cost-cutting and innovative approaches: the FOCO-CAR process reduces production time and costs (if the factory in Suzhou operates at full capacity, the cost per batch would be lower than competitors’); the iMAGIC platform explores “in vivo CAR-T” therapy, which involves directly administering virus vectors to modify T cells without the need for blood drawing, potentially enabling the development of off-the-shelf products.
III. Cash Crisis: The 21-Month Deadline for an IPO
CAR-T research and development is extremely costly. Yimu Feng incurred losses of 71.31 million yuan in 2024, 115 million yuan in 2025, and 109 million yuan in the first half of 2026 (with R&D accounting for 71% of expenses). As of June 2026, the company only has 472 million yuan in cash (including 175 million yuan from the latest round of financing). At the current rate of expenditure, its funds will last for 21 months, and since IMC002’s market application is not until 2027, it must rely on an IPO to secure additional funding.
IV. Three Major Commercialization Hurdles: Can It Make Money After Going Public?
While an IPO may solve the funding issue, the real challenge is selling the products. Yimu Feng faces three key obstacles:
1. Competitive Pressure: Competitors such as Kexi Pharmaceutical’s CLDN18.2 CAR-T (CT041) were approved in June 2026 and are already available in hospitals, gaining an advantage by reaching patients earlier. Although IMC002 has promising clinical data, its performance in the real world is still unknown.
2. IP Licensing: The core technology for IMC002 is licensed from a third party, meaning the company must pay a percentage of sales and significant milestone fees. High costs associated with IP licensing further compress profits.
3. Pricing: With prices in the millions of yuan, patients may struggle to afford the treatment, especially considering strict healthcare cost controls. Even with government subsidies, many patients will still have to cover the difference out of pocket. Lowering prices could reduce profits, creating a dilemma.
Conclusion: From a Promising Story to Real-World Challenges
Yimu Feng represents the typical challenges faced by Chinese innovative pharmaceutical companies—strong teams, enthusiastic capital, and impressive clinical data, but as the company approaches market launch, the pressure of commercialization increases. The IPO is just the first step; success will depend on whether IMC002 can be successfully launched, costs can be reduced, and patients can afford the treatment. The 21-month timeframe, competing products, IP licensing fees, and high pricing issues will not disappear after going public; the market will ultimately determine the company’s value based on sales and profitability.
(The entire analysis is written in plain language, making it easy for non-financial readers to understand the key points.)